Cargando…

Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes

In this paper, we present the development of a computer-based repurposing approach to identify FDA-approved drugs that are potentially able to interfere with irisin dimerization. It has been established that altered levels of irisin dimers are a pure hallmark of lipodystrophy (LD) syndromes. Accordi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flori, Lorenzo, Brogi, Simone, Sirous, Hajar, Calderone, Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145865/ https://www.ncbi.nlm.nih.gov/pubmed/37108741 http://dx.doi.org/10.3390/ijms24087578

Ejemplares similares

Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors
por: Sirous, Hajar, et al.
Publicado: (2020)

A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
por: Battah, Basem, et al.
Publicado: (2019)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
por: Zulfiqar, Zikra, et al.
Publicado: (2020)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
por: Chittepu, Veera C. S. R., et al.
Publicado: (2019)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
por: Mee-udorn, Pitchayathida, et al.
Publicado: (2023)

Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022)

Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers
por: Snell, Terry W., et al.
Publicado: (2018)

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats [Retraction]
Publicado: (2022)

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches
por: Mohammed, Omima S., et al.
Publicado: (2023)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

In Silico Drug Repurposing Approach: Investigation of Mycobacterium tuberculosis FadD32 Targeted by FDA-Approved Drugs
por: Ngidi, Nolwazi Thobeka Portia, et al.
Publicado: (2022)

Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay
por: Diallo, Bakary N’tji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jfu3h3f283lc8eb6ia3f8iphmm